Search Results

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.

Chiesi Global Rare Diseases announced a U.S. Networkwide Sponsorship of BioInnovation Labs, the leading developer and operator of life science coworking spaces with 12 active facilities and a growing network in the U.S. and internationally.

Orion Corporation and Glykos Finland Oy announced that they have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates.

Faron Pharmaceuticals Oy announces that Dr. Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday January 11, 2024, at 12pm PT, in San Francisco.

Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany’s PEI to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma.

ERS Genomics Limited, the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy, a biotechnology company developing stem cell based therapies for corneal blindness, announced a non-exclusive CRISPR/Cas9 license agreement.

Immugenia Inc. has announced that adMare BioInnovations, ACET Capital 2, and Sherbrooke Innopole have joined forces to support the development of immunity therapy programs based on the work of Dr. Elie Haddad, clinical researcher at CHU Sainte-Justine and professor at the Université de Montréal’s pediatrics department.

Valo Therapeutics Oy announces it is the first biotech company in Europe to install and use the Bruker Corporation’s new timsTOF Ultra mass spectrometer and liquid chromatography platform, which provides transformative speed and sensitivity for antigen identification in connection with ValoTx’s PeptiCHIP technology.

Faron Pharmaceuticals Oy announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia and myelodysplastic syndrome on Wednesday, October 11 at 08.00 EST/13.00 BST/15.00 EEST.